This is in opposition to the previous literature, which noted ENTPD1 as a key mediator of the purinergic pathway in the form of ENTPD1/CD39, an ectonucleotide enzyme that scavenges pro-inflammatory ATP and ADP into AMP in critically ill COVID-19 patients. This evidence concerns the gene ENTPD1 and COVID-19.